AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. AbbVie’s Irish operations employ more than 400 people across five sites in Ireland.
AbbVie Ireland operates two separate plants in Sligo employing more than 200 staff. The company’s high containment facility on the Manorhamilton Road was established in 2002 and has dedicated capabilities for potent active pharmaceutical ingredient and drug product manufacturing. This facility recently underwent a significant €85 million expansion that doubled its footprint and provided additional capability to support AbbVie’s new product introductions.
AbbVie has a second manufacturing site in Sligo at Ballytivnan. Founded in 1974, this plant is now a global centre of excellence for design control and precision engineering in the production of drug delivery devices.
Our plant in Carrigtwohill is a ‘bulk tablet’ finish facility, which manufactures solid and capsule formulations. This advanced facility employs the most innovative new technologies, delivering products and processes that support AbbVie’s wider global needs. These range from small scale clinical trial supply to large commercial manufacturing.
AbbVie’s commercial office is located at the Liffey Valley in west Dublin where more than 70 people work in the sale, supply, distribution and marketing of the company’s Irish-licensed products. A second office in Santry is an international base for a range of AbbVie manufacturing and engineering services. These support company plants all around the world.